Regulation of PD-L1 expression in cancer and clinical implications in immunotherapy

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Programmed cell death protein 1 (PD-1)/PD-L1 immune checkpoint blockade is a key cancer immunotherapy.
• Despite clinical success, many patients exhibit low response rates and drug resistance.
• Understanding PD-L1 expression regulation is crucial for improving immunotherapy efficacy.

Purpose of the Study:

• To systematically review the regulatory mechanisms of PD-L1 expression in tumor cells.
• To explore the clinical implications of PD-L1 regulation in cancer immunotherapy.
• To identify novel therapeutic avenues for enhancing PD-1/PD-L1 blockade efficacy.

Main Methods:

• Comprehensive literature review of PD-L1 regulation.
• Analysis of genomic, epigenetic, transcriptional, translational, and posttranslational mechanisms.
• Discussion of clinical applications and challenges.

Main Results:

• PD-L1 expression is modulated through multiple layers of biological control.
• Genomic alterations, epigenetic modifications, and various regulatory pathways influence PD-L1 levels.
• Clinical data highlights the complexity of PD-L1 regulation in treatment response.

Conclusions:

• A deep understanding of PD-L1 regulatory networks is essential for overcoming immunotherapy resistance.
• Targeting specific PD-L1 regulatory pathways may enhance patient response to PD-1/PD-L1 blockade.
• This review provides a framework for developing next-generation cancer immunotherapies.